The most optimistic approval timeline points to late the following year, with commercial availability potentially in the year after that

Neelakantan et al., NNMT inhibition reverses diet-induced obesity in mice (2018) Babula et al., NNMT inhibition mitigates obesity-related metabolic dysfunction: fat mass, glucose tolerance, hepatic steatosis, pharmacokinetics and off-target screen (Diabetes Obes Metab, 2024) Dimet-Wiley et al., NNMT inhibition mimics and boosts exercise-mediated muscle improvements in aged mice (Sci Rep, 2024) NNMT inhibition and muscle function in aged mice (2019) Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice (2022): the diet-switch combination study Awosemo et al., rat pharmacokinetics of 5-amino-1MQ (2021) NNMT in metabolism and disease: review Sigma-Aldrich: 5-Amino-1MQ iodide product data (CAS 42464-96-0) FDA: bulk drug substances used in compounding under section 503A Disclaimer: Informational and research purposes only, not medical advice
J Hepatol 2025;83:13791391: 10.1016/j.jhep.2025.06.011
Manufacturing is done in FDA registered facilities with proper quality control protocols
BPC-157 (5mg) Certificate of Analysis BPC-157 (10mg) Certificate of Analysis
Storage Quick Reference Pro tip: With multiple vials, unopened ones are kept in the freezer and only what will be used within 3-4 weeks is reconstituted